
Farbod Darvishian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7125182/publications.pdf Version: 2024-02-01



FARROD DARVISHIAN

#	Article	IF	CITATIONS
1	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research, 2018, 24, 5347-5356.	7.0	253
2	Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma. PLoS ONE, 2012, 7, e29336.	2.5	250
3	A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis. Cancer Cell, 2017, 31, 804-819.e7.	16.8	233
4	FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nature Cell Biology, 2015, 17, 322-332.	10.3	134
5	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. Molecular Cell, 2017, 68, 731-744.e9.	9.7	90
6	Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma. Cancer Immunology Research, 2015, 3, 278-287.	3.4	81
7	Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. Journal of the National Cancer Institute, 2019, 111, 180-188.	6.3	74
8	A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. Clinical Cancer Research, 2015, 21, 4903-4912.	7.0	73
9	Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Human Pathology, 2016, 57, 116-125.	2.0	71
10	Identification of Metastasis-Suppressive microRNAs in Primary Melanoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	47
11	Histology-Specific MicroRNA Alterations in Melanoma. Journal of Investigative Dermatology, 2012, 132, 1860-1868.	0.7	46
12	BET and BRAF inhibitors act synergistically against BRAF―mutant melanoma. Cancer Medicine, 2016, 5, 1183-1193.	2.8	41
13	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports, 2019, 9, 8572.	3.3	36
14	Micro <scp>RNA</scp> â€125a promotes resistance to <scp>BRAF</scp> inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell and Melanoma Research, 2017, 30, 328-338.	3.3	34
15	Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. American Journal of Translational Research (discontinued), 2009, 1, 35-43.	0.0	33
16	Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model. Breast Cancer Research, 2019, 21, 42.	5.0	30
17	Atypia on breast core needle biopsies: reproducibility and significance. Annals of Clinical and Laboratory Science, 2009, 39, 270-6.	0.2	27
18	Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. Journal of Translational Medicine, 2016, 14, 299.	4.4	26

FARBOD DARVISHIAN

#	Article	IF	CITATIONS
19	Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. Journal of Translational Medicine, 2014, 12, 342.	4.4	24
20	Revisiting the Clinical and Biologic Relevance ofÂPartial PTEN Loss in Melanoma. Journal of Investigative Dermatology, 2019, 139, 430-438.	0.7	22
21	Pathologic Evaluation of Breast Tissue From Transmasculine Individuals Undergoing Gender-Affirming Chest Masculinization. Archives of Pathology and Laboratory Medicine, 2020, 144, 888-893.	2.5	22
22	Oxidative Phosphorylation Promotes Primary Melanoma Invasion. American Journal of Pathology, 2020, 190, 1108-1117.	3.8	20
23	Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial. Breast Cancer Research, 2014, 16, 463.	5.0	17
24	The histone demethylase PHF8 regulates TGFβ signaling and promotes melanoma metastasis. Science Advances, 2022, 8, eabi7127.	10.3	17
25	Functional analysis of RPS27 mutations and expression in melanoma. Pigment Cell and Melanoma Research, 2020, 33, 466-479.	3.3	14
26	TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors. Journal of Investigative Dermatology, 2020, 140, 1609-1618.e7.	0.7	14
27	Angiosarcoma of the Breast Masquerading as Hemangioma: Exploring Clinical and Pathological Diagnostic Challenges. Archives of Plastic Surgery, 2015, 42, 261-263.	0.9	14
28	Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma. Modern Pathology, 2021, 34, 562-571.	5.5	13
29	Enhanced immunohistochemical detection of neural infiltration in primary melanoma: is there a clinical value?. Human Pathology, 2014, 45, 1656-1663.	2.0	12
30	Microglandular adenosis is an advanced precursor breast lesion with evidence of molecular progression to matrix-producing metaplastic carcinoma. Human Pathology, 2019, 85, 65-71.	2.0	12
31	The Relationship of Breast Density and Positive Lumpectomy Margins. Annals of Surgical Oncology, 2019, 26, 1729-1736.	1.5	8
32	Localized amyloidosis: A diagnostic pitfall in breast pathology. Pathology Research and Practice, 2019, 215, 152699.	2.3	8
33	Association between Kiâ€67 expression and clinical outcomes among patients with clinically nodeâ€negative, thick primary melanoma who underwent nodal staging. Journal of Surgical Oncology, 2018, 118, 150-156.	1.7	7
34	Molecular analysis of encapsulated papillary carcinoma of the breast with and without invasion. Human Pathology, 2021, 111, 67-74.	2.0	7
35	Genetic profile of primary mucinous cystadenocarcinoma of the breast—A case report. Breast Journal, 2021, 27, 731-734.	1.0	7
36	Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort. Journal of Investigative Dermatology, 2022, 142, 2733-2743.e9.	0.7	7

Farbod Darvishian

#	Article	IF	CITATIONS
37	Multifocal Invasive Ductal Cancer: Distinguishing Independent Tumor Foci From Multiple Satellites. International Journal of Surgical Pathology, 2017, 25, 298-303.	0.8	6
38	Benign Fibromyxoid Lesion of the Breast: A Distinct Entity From Benign Spindle Cell Tumors of the Mammary Stroma?. International Journal of Surgical Pathology, 2018, 26, 488-493.	0.8	5
39	Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity. Modern Pathology, 2022, 35, 1370-1382.	5.5	5
40	Missing targets after nipple-sparing mastectomy: A multi-disciplinary approach to avoid an undesirable outcome. Breast Journal, 2018, 24, 678-679.	1.0	3
41	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma Journal of Clinical Oncology, 2012, 30, 2589-2589.	1.6	3
42	Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer, 2015, 15, 926.	2.6	2
43	A Note of Caution. International Journal of Surgical Pathology, 2015, 23, 549-552.	0.8	2
44	Breast Cancer Risk Factors and Circulating Anti-Müllerian Hormone Concentration in Healthy Premenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4542-e4553.	3.6	2
45	Bone metastasis to predict treatment response rate and overall survival of patients with metastatic melanoma Journal of Clinical Oncology, 2018, 36, e21585-e21585.	1.6	2
46	Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC) Journal of Clinical Oncology, 2013, 31, 60-60.	1.6	1
47	Association of melanoma expression of matrix metalloproteinase-23 with blunted tumor immunity and poor responses to immunotherapy Journal of Clinical Oncology, 2015, 33, e20057-e20057.	1.6	1
48	Using digital-image analysis of tumor-infiltrating lymphocytes to predict survival outcomes in primary melanoma Journal of Clinical Oncology, 2020, 38, 10066-10066.	1.6	1
49	Targeting BET proteins in melanoma: A novel treatment approach Journal of Clinical Oncology, 2013, 31, 9091-9091.	1.6	1
50	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma Journal of Clinical Oncology, 2014, 32, 9086-9086.	1.6	1
51	Targeting EZH2 in acral lentiginous melanoma (ALM) Journal of Clinical Oncology, 2017, 35, 9534-9534.	1.6	1
52	Revisiting multifocal breast cancer: a clonality study of ductal carcinoma using whole exome sequencing. Human Pathology, 2019, 94, 71-77.	2.0	0
53	Early alterations of microRNA expression to predict and modulate melanoma metastasis Journal of Clinical Oncology, 2012, 30, 8550-8550.	1.6	0
54	Prognostic value of mitosis-specific antibodies and computer image analysisÂin calculatingÂmitotic rateÂin melanoma Journal of Clinical Oncology, 2012, 30, e19003-e19003.	1.6	0

Farbod Darvishian

#	Article	IF	CITATIONS
55	TILs in metastatic melanoma tumors: A biomarker for immunotherapy?. Journal of Clinical Oncology, 2012, 30, 8589-8589.	1.6	Ο
56	Impact of age on treatment of primary melanoma patients Journal of Clinical Oncology, 2013, 31, 9054-9054.	1.6	0
57	Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC) Journal of Clinical Oncology, 2013, 31, 11106-11106.	1.6	Ο
58	Analysis of plasma-based <i>BRAF</i> and <i>NRAS</i> mutation detection in patients with stage III and IV melanoma Journal of Clinical Oncology, 2013, 31, 9023-9023.	1.6	0
59	Preclinical testing supports combined BET and BRAF inhibition as a promising therapeutic strategy for melanoma Journal of Clinical Oncology, 2014, 32, 9072-9072.	1.6	Ο
60	Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma Journal of Clinical Oncology, 2014, 32, 3030-3030.	1.6	0
61	Tumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas Journal of Clinical Oncology, 2015, 33, e20042-e20042.	1.6	Ο
62	Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival Journal of Clinical Oncology, 2015, 33, 9070-9070.	1.6	0
63	Metastatic melanoma outcomes in the era of commercially available targeted therapy and immunotherapy Journal of Clinical Oncology, 2016, 34, e21017-e21017.	1.6	Ο
64	Prognostic value of mitoses in thick primary melanoma Journal of Clinical Oncology, 2016, 34, e21046-e21046.	1.6	0
65	Impact of aging on immune response and survival in melanoma Journal of Clinical Oncology, 2016, 34, e21079-e21079.	1.6	Ο
66	The impact of clinical stage at primary melanoma diagnosis on post-recurrence survival Journal of Clinical Oncology, 2016, 34, 9550-9550.	1.6	0
67	A threshold of clinically significant reduced PTEN expression in melanoma Journal of Clinical Oncology, 2016, 34, e21063-e21063.	1.6	Ο
68	Analysis of TERT promoter mutations, polymorphisms, clinicopathologic features and recurrence-free survival in primary melanoma Journal of Clinical Oncology, 2016, 34, e21065-e21065.	1.6	0
69	Identification of differentially expressed genes associated with clinical response after treatment of breast cancer skin metastases with imiquimod Journal of Clinical Oncology, 2017, 35, e12541-e12541.	1.6	Ο